ClinicalTrials.gg
RecruitingNCT07312786Updated May 14, 2026

Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors

An interventional study of virtual self-management intervention in Breast Cancer Survivor and Colorectal Cancer Survivors, sponsored by Nova Scotia Health Authority. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.

Planned enrollment
557th of 787
60 · median 155
Started
2026
with 23 others
No phase
204 of 907
37 open now
Primary completion
2026-12
later than 113 of 256 live
Registered
894th of 907
by date

Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 557th largest by planned enrollment of the 787 interventional ones that give a count, is one of 24 that started in 2026, is one of 204 with no phase, reaches primary completion later than 113 of the 256 other live ones, and was the 894th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

133 more — sign in →

All 139 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Breast Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to determine the feasibility of implementing a mobile health application for breast and colorectal cancer survivors following primary treatment. Developed in collaboration with Seamless MD, the intervention acts as an information hub, providing users with timely and evidence-based information related to follow-up care as well as health system/community-based resources and programs to meet their needs during this period of care. The goal of the intervention is to encourage open communication regarding survivorship expectations and provide survivors with appropriate information and support to meet their needs.

This study will:

  1. Test the feasibility of implementing the virtual intervention at two cancer centres in Atlantic Canada (Nova Scotia and New Brunswick)
  2. Gather feedback regarding the intervention from cancer survivors and healthcare providers.

Participants will have access to the intervention for a period of six months. Questionnaires will be distributed to participants through the intervention at baseline, 90 days, and 180 days to assess user experience. Semi-structured interviews will be conducted with select survivor participants and healthcare providers (oncology and primary care) to determine the feasibility and acceptability of this intervention.

03

Conditions studied

  • Breast Cancer Survivor
  • Colorectal Cancer Survivors

Keywords

  • Cancer Survivorship
  • SeamlessMD
  • Supported self-management
  • Survivorship app
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Adults older than 18 years, capable of providing
  • Diagnosed with stage I-III breast or colorectal cancer, and have completed primary treatment for their cancer (surgery and/or systemic or radiation therapy) 6 months - 5 years ago
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    virtual self-management intervention

    Behavioral: virtual self-management intervention

Interventions

  • Behavioralvirtual self-management intervention

    The intervention is a supportive information and self-management tool housed on the SeamlessMD mobile app, created in collaboration with the SeamlessMD development program and informed by foundational research. The application will be used as an information hub and self-management/navigation tool alongside usual care, to address the physical, psychosocial, and practical needs of breast and colorectal cancer survivors. Note that the intervention will not seek to change or impact a survivor's follow-up care plan, as decided upon by the participant and their care team.

06

What researchers measure

Primary outcomes

  1. Recruitment

    Case report forms will be used to track recruitment metrics. The following demographics will be collected to monitor the diversity of those participating: cancer type (breast, colorectal), stage at diagnosis (in situ, stage 1, stage 2, stage 3, do not know), age (in years, prefer not to say), sex assigned at birth (male, female, intersex, prefer not to say), gender (man, woman, non-binary, other, prefer not to say), residence (rural, suburban, urban, prefer not to say), and highest level of education achieved (less than high school, high school, some post-secondary (college or university), diploma or degree, prefer not to say).

    Time frame: During enrollment

  2. Retention

    Case report forms will be used to track retention metrics.

    Time frame: Enrollment to day 180

  3. Usage of the Intervention

    Usage metrics will be collected using the SeamlessMD software to determine the following: 1) how often the intervention was accessed by participants, 2) what elements of the intervention were accessed most, and 3) what elements of the program were utilized the least.

    Time frame: Baseline to day 180

  4. Survivor and Provider Acceptability and Experience

    Assessed via one-on-one semi-structured interviews with a sub-sample of study participants and providers at both study sites. Semi-structured interviews were chosen over focus groups for this component because the research team is seeking individual experiences with the intervention. Interviews will be carried out by a member of the research team on video conferencing software using a predetermined interview guide and will take approximately 45 minutes. The questions will center around the study participant's follow-up care experience while being supported by the intervention. Interviews with providers will focus on the feasibility and acceptability of the supportive self-management tool.

    Time frame: Interviews with survivor participants will be conducted after having access to the intervention for 180 days.

Secondary outcomes

  1. Fear of Recurrence

    Will be assessed using the 6-item Cancer Worry Scale, a validated patient-reported instrument. Cancer Worry Scale (CWS) scores range from 6 to 24 points. A score of 6 points indicates low worry, while a score of 24 points indicates very high worry.

    Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.

  2. Patient Activation

    Will be assessed with the 13-item Patient Activation Measure (PAM), a validated patient-reported instrument. PAM includes 13 questions that produce a score on a 0-100 scale, which correlates with 1 of 4 activation levels. A level 1 score indicates low activation, while a level 4 score indicates a high activation.

    Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.

  3. Information Provision

    There are no validated instruments to assess information provision on its own. Therefore, these will be assessed using modified survey items from the Canadian Transitions Survey, a national survey on survivors' needs and experiences after completing cancer treatment.

    Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.

07

Study locations

1 of 2 sites recruiting
  • Saint John Regional Hospital
    Saint John, New Brunswick, Canada
    Not yet recruiting
  • Centre for Clinical Research QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 8 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 31, 2025
StartActual
Apr 20, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312786
Collaborators
Canadian Cancer Society (CCS)
Responsible party
Robin Urquhart (NSHealth Affiliate Scientist, Nova Scotia Health Authority) — Principal investigator
First posted
Dec 31, 2025
Start date
Apr 20, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion